Braveheart Bio (NASDAQ:BRVE) Trading 8.1% Higher - Here's What Happened

Key Points

• Braveheart Bio shares rose 8.1% to about $23.20 in midday trading, although volume was 58% below the average session level.
• Analyst sentiment remains positive, with five Buy ratings and one Hold rating producing a “Moderate Buy” consensus and an average price target of $45.25.
• The company reported quarterly EPS of -$2.51, missing the consensus estimate of -$0.25, while insiders purchased 8.75 million shares worth approximately $157.5 million over the past 90 days.

Braveheart Bio, Inc. (NASDAQ:BRVE - Get Free Report) shares rose 8.1% during mid-day trading on Thursday . The stock traded as high as $22.47 and last traded at $23.1990. 194,514 shares were traded during mid-day trading, a decline of 58% from the average session volume of 462,762 shares. The stock had previously closed at $21.46.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Zacks Research raised Braveheart Bio to a "hold" rating in a research note on Tuesday, September 1st. Jefferies Financial Group initiated coverage on shares of Braveheart Bio in a report on Monday, August 31st. They set a "buy" rating and a $48.00 price target for the company. Wall Street Zen raised shares of Braveheart Bio to a "hold" rating in a report on Saturday, August 15th. Stifel Nicolaus assumed coverage on shares of Braveheart Bio in a research note on Monday, August 31st. They set a "buy" rating and a $45.00 price objective for the company. Finally, Cantor Fitzgerald began coverage on Braveheart Bio in a research note on Monday, August 31st. They issued an "overweight" rating and a $40.00 target price on the stock. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $45.25.

Braveheart Bio Trading Up 10.0%

Braveheart Bio (NASDAQ:BRVE - Get Free Report) last released its earnings results on Tuesday, September 8th. The company reported ($2.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by ($2.26). On average, analysts forecast that Braveheart Bio, Inc. will post -1.48 EPS for the current year.

Insider Transactions at Braveheart Bio

In related news, major shareholder Bio Fund Iv L.P. Ah bought 1,100,000 shares of the business's stock in a transaction dated Friday, August 7th. The shares were purchased at an average cost of $18.00 per share, with a total value of $19,800,000.00. Following the completion of the purchase, the insider owned 10,232,420 shares in the company, valued at approximately $184,183,560. The trade was a 12.05% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Erez Chimovits purchased 1,940,000 shares of Braveheart Bio stock in a transaction dated Friday, August 7th. The shares were bought at an average price of $18.00 per share, with a total value of $34,920,000.00. Following the completion of the acquisition, the director directly owned 11,901,826 shares of the company's stock, valued at approximately $214,232,868. This represents a 19.47% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders purchased 8,751,942 shares of company stock worth $157,534,956.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.